Shares of ContraFect Corporation (NASDAQ:CFRX) were down 12.5% during mid-day trading on Friday . The company traded as low as $0.80 and last traded at $0.88. Approximately 607,596 shares traded hands during trading, an increase of 554% from the average daily volume of 92,903 shares. The stock had previously closed at $1.00.

Separately, Maxim Group reaffirmed a “hold” rating on shares of ContraFect Corporation in a research report on Thursday, May 25th.

The company has a 50-day moving average price of $1.19 and a 200-day moving average price of $1.52. The stock’s market capitalization is $64.45 million.

ContraFect Corporation (NASDAQ:CFRX) last announced its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.07) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.11. Analysts anticipate that ContraFect Corporation will post ($0.43) EPS for the current fiscal year.

In related news, Director Sol J. Barer acquired 40,000 shares of the business’s stock in a transaction dated Tuesday, July 25th. The stock was acquired at an average price of $1.24 per share, with a total value of $49,600.00. Following the completion of the transaction, the director now owns 815,933 shares of the company’s stock, valued at $1,011,756.92. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have bought 50,800 shares of company stock valued at $62,992 in the last ninety days. 9.30% of the stock is owned by company insiders.

A hedge fund recently bought a new stake in ContraFect Corporation stock. Westfield Capital Management Co. LP acquired a new stake in shares of ContraFect Corporation (NASDAQ:CFRX) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 149,600 shares of the biotechnology company’s stock, valued at approximately $269,000. Westfield Capital Management Co. LP owned about 0.36% of ContraFect Corporation as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 24.45% of the company’s stock.

WARNING: This news story was originally published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at

About ContraFect Corporation

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza.